^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    PD-L1 expression positive (≥50%)…squamous cell carcinoma…Useful in certain circumstances...Nivolumab + ipilimumab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    PD-L1 expression positive (≥50%)…squamous cell carcinoma…Other recommended...Nivolumab + ipilimumab + paclitaxel + carboplatin
    Secondary therapy:
    carboplatin + bisphosphonate bound paclitaxel